Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $15.58M rose 49.0% year over year, ahead of the +35.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 37.2% from the prior quarter. Over 3 fiscal years it compounded at +36.5% a year.

Context

  • Stock-based compensation amounted to 83.3% of revenue in FY2025, up 31.4 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +49.0% holds above the trailing-twelve-month pace of +35.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.58M+37.2% QoQ
Last fiscal yearDec 2025
$43.18M+30.4% YoY
LTMMar 2026
$48.31M+35.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.0%——
1 year+30.4%——
3-year CAGR+36.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
43.18M USD
Year-over-year change
+30.4%
4-year CAGR
+30.3%

Stock-Based Compensation vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.8% is the 3rd highest of 10, against a peer median of +9.3%.
  • Stock-based compensation amounts to 92.8% of revenue for OCUL, versus a peer median of 109.8%.
OCUL Competitors
Stock-Based Compensation for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GKOSGlaukos CorporationLTM Jun 2026$80.22M USD+36.6%+17.9%13.1%
BLCOBausch + Lomb CorporationLTM Jun 2026$72M USD-33.9%+33.9%1.4%
KODKodiak Sciences Inc.LTM Sep 2026$63.89M USD+17.9%-17.8%—
OCULOcular Therapeutix, Inc.LTM Mar 2026$48.31M USD+35.8%+36.5%92.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$31.69M USD-0.5%+25.3%416.2%
STAASTAAR Surgical CompanyLTM Apr 2026$29.4M USD+9.3%+14.5%10.1%
OCSOculis Holding AGLTM Mar 2026CHF 18.42M CHF+63.4%+171.2%3653.8%
HROWHarrow Health, Inc.LTM Mar 2026$11.78M USD-34.6%+16.2%4.4%
OCGNOcugen, Inc.LTM Mar 2026$9.22M USD+22.1%-9.9%206.5%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M USD-37.3%+4.9%1543.3%
SGPSpyGlass Pharma, Inc. Common StockFY2025$2.79M USD———
Peer median (excluding OCUL) —+9.3%+16.2%109.8%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
Deferred Income Tax00000
Stock-Based Compensation14.98M16.96M17.83M33.11M43.18M
Change in Working Capital(2.9M)1.35M(7.41M)(10.23M)7.71M
Accounts Receivables(8.88M)(190K)(4.85M)(6.21M)1.74M
Inventory(49K)(724K)(331K)(735K)(524K)
Accounts Payables1.8M(621K)583K(318K)(887K)
Other Working Capital4.24M2.88M(2.81M)(2.97M)7.38M
Other Non-Cash Items(73.49M)(8.99M)(2.9M)32.16M5.84M
Operating Cash Flow(65.55M)(59.6M)(70.23M)(134.68M)(204.88M)
Capital Expenditures(1.19M)(3.72M)(6.09M)(1.29M)(12.01M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0000130K
Investing Cash Flow(1.19M)(3.72M)(6.09M)(1.29M)(11.88M)
Debt Repayment(445K)056.35M316.35M0
Common Stock Issued985K940K118.11M316.35M561.72M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.31M514K(4.63M)(300.6M)0
Financing Cash Flow2.85M1.45M169.83M332.11M561.72M
Effect of Forex Changes00000
Net Change in Cash(63.89M)(61.86M)93.51M196.15M344.96M
Free Cash Flow(66.74M)(63.32M)(76.32M)(135.97M)(216.89M)

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.